Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.36 Insider Own46.72% Shs Outstand13.02M Perf Week2.03%
Market Cap7.23M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float8.53M Perf Month7.57%
Income-4.85M PEG- EPS next Q-0.09 Inst Own10.60% Short Float0.09% Perf Quarter-28.29%
Sales0.00M P/S- EPS this Y41.94% Inst Trans- Short Ratio0.03 Perf Half Y-12.17%
Book/sh0.39 P/B1.17 EPS next Y-27.78% ROA-84.07% Short Interest0.01M Perf Year-70.85%
Cash/sh0.41 P/C1.10 EPS next 5Y- ROE-94.50% 52W Range0.36 - 3.14 Perf YTD-38.94%
Dividend Est.- P/FCF- EPS past 5Y- ROI-78.27% 52W High-85.61% Beta1.71
Dividend TTM- Quick Ratio8.01 Sales past 5Y0.00% Gross Margin- 52W Low25.50% ATR (14)0.04
Dividend Ex-Date- Current Ratio8.01 EPS Y/Y TTM65.18% Oper. Margin0.00% RSI (14)47.78 Volatility11.91% 9.27%
Employees4 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q76.46% Payout- Rel Volume0.33 Prev Close0.46
Sales Surprise- EPS Surprise-33.33% Sales Q/Q- EarningsMay 10 BMO Avg Volume227.10K Price0.45
SMA20-1.04% SMA501.21% SMA200-28.14% Trades Volume74,647 Change-1.57%
Date Action Analyst Rating Change Price Target Change
Dec-18-23Initiated Noble Capital Markets Outperform $4
Jun-12-24 07:00AM
Jun-11-24 04:15PM
Jun-03-24 09:00AM
May-23-24 09:00AM
01:53PM Loading…
May-09-24 01:53PM
Apr-11-24 04:30PM
Apr-09-24 09:00AM
Mar-11-24 09:00AM
Feb-26-24 09:00AM
Feb-08-24 09:00AM
Jan-31-24 09:00AM
Jan-24-24 09:00AM
Jan-04-24 09:00AM
09:00AM Loading…
Dec-19-23 09:00AM
Dec-12-23 09:00AM
Nov-30-23 04:15PM
Nov-09-23 09:00AM
Oct-16-23 08:38AM
Oct-09-23 04:15PM
Sep-05-23 08:00AM
Aug-30-23 08:00AM
Aug-28-23 04:15PM
Aug-10-23 09:00AM
Aug-01-23 09:00AM
Jul-24-23 09:00AM
Jul-14-23 03:02PM
Jul-12-23 03:17PM
Jun-28-23 06:23AM
09:00AM Loading…
Jun-01-23 09:00AM
May-10-23 09:00AM
May-09-23 04:30PM
Mar-30-23 09:00AM
Mar-09-23 09:00AM
Feb-08-23 09:00AM
Feb-06-23 09:00AM
Feb-01-23 09:00AM
Jan-24-23 02:11PM
Jan-23-23 11:39AM
Jan-20-23 09:31AM
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MURPHY JOHN RAYMONDDirectorOct 05 '23Buy0.692,6691,842614,792Oct 06 05:32 PM
MURPHY JOHN RAYMONDDirectorOct 04 '23Buy0.7017,33112,132612,123Oct 06 05:32 PM
Pham Quang XCEO and ChairmanSep 05 '23Buy0.9040,00036,1883,410,000Sep 06 03:28 PM
Pham Quang XCEO and ChairmanSep 01 '23Buy0.9170,00063,9453,370,000Sep 05 06:05 AM